ERBB2 and neoplasm: In a non-randomized, phase II trial, the addition of a monocyte-derived, autologous tumor-lysate pulsed DC vaccine to neoadjuvant chemotherapy (NAC) was evaluated in 39 treatment-naïve patients with stage I-III HER2-negative BC, of whom 36% were of the TNBC subtype.